Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Slovin, S. F.
Right arrow Articles by Scher, H. I.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Slovin, S. F.
Right arrow Articles by Scher, H. I.
Journal of Clinical Oncology, Vol 21, Issue 23 (December), 2003: 4292-4298
© 2003 American Society for Clinical Oncology

Fully Synthetic Carbohydrate-Based Vaccines in Biochemically Relapsed Prostate Cancer: Clinical Trial Results With {alpha}-N-Acetylgalactosamine-O-Serine/Threonine Conjugate Vaccine

Susan F. Slovin, Govindaswami Ragupathi, Cristina Musselli, Krystyna Olkiewicz, David Verbel, Scott D. Kuduk, Jacob B. Schwarz, Dalibor Sames, Samuel Danishefsky, Philip O. Livingston, Howard I. Scher

From the Division of Genitourinary Oncology and Laboratory of Solid Tumor Immunology, Laboratory of Vaccinology, Division of Clinical Immunology, Department of Medicine, Department of Biostatistics, and the Laboratory of Bio-Organic Chemistry, Memorial Sloan-Kettering Cancer Center, New York, NY.

Address reprint requests to Susan F. Slovin, MD, PhD, Genitourinary Solid Tumor Service, 1275 York Ave, New York, NY 10021; e-mail: slovins{at}mskcc.org.

Purpose: We report the synthesis of a mucin-related O-linked glycopeptide, {alpha}-N-acetylgalactosamine-O-serine/threonine (Tn), which is highly simplistic in its structure and can induce a relevant humoral response when given in a trimer or clustered (c) formation. We tested for an antitumor effect, in the form of a change in the posttreatment versus pretreatment prostate-specific antigen (PSA) slopes, that might serve as a surrogate for effectiveness of vaccines in delaying the time to radiographic progression.

Methods: We compared the antibody response to immunization with two conjugates, Tn(c)-keyhole limpet hemocyanin (KLH) and Tn(c)-palmitic acid (PAM) with the saponin immunologic adjuvant QS21, in a phase I clinical trial in patients with biochemically relapsed prostate cancer. Patients received Tn(c)-KLH vaccine containing either 3, 7, or 15 µg of Tn(c) per vaccination. Ten patients received 100 µg of Tn(c)-PAM. QS21 was included in all vaccines. Five vaccinations were administered subcutaneously during 26 weeks with an additional booster vaccine at week 50.

Results: Tn(c), when given with the carrier molecule KLH and QS21, stimulated the production of high-titer immunoglobulin M (IgM) and IgG antibodies. Inferior antibody responses were seen with T(c)-PAM. There was no evidence of enhanced immunogenicity with increasing doses of vaccine. An antitumor effect in the form of a decline in posttreatment versus pretreatment PSA slopes was also observed.

Conclusion: A safe synthetic conjugate vaccine in a trimer formation was developed that can break immunologic tolerance by inducing specific humoral responses. It seemed to affect the biochemical progression of the disease as determined by a change in PSA log slope.

Supported by the Association for the Cure of Cancer of the Prostate (CaP CURE) and the PepsiCo Foundation.




This article has been cited by other articles:


Home page
Clin. Cancer Res.Home page
P. J. Sabbatini, G. Ragupathi, C. Hood, C. A. Aghajanian, M. Juretzka, A. Iasonos, M. L. Hensley, M. K. Spassova, O. Ouerfelli, D. R. Spriggs, et al.
Pilot Study of a Heptavalent Vaccine-Keyhole Limpet Hemocyanin Conjugate plus QS21 in Patients with Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer
Clin. Cancer Res., July 15, 2007; 13(14): 4170 - 4177.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
P. Sabbatini and K. Odunsi
Immunologic Approaches to Ovarian Cancer Treatment
J. Clin. Oncol., July 10, 2007; 25(20): 2884 - 2893.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
H. F. Valenzuela, K. E. Pace, P. V. Cabrera, R. White, K. Porvari, H. Kaija, P. Vihko, and L. G. Baum
O-Glycosylation Regulates LNCaP Prostate Cancer Cell Susceptibility to Apoptosis Induced by Galectin-1
Cancer Res., July 1, 2007; 67(13): 6155 - 6162.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
J. W. Simons, M. A. Carducci, B. Mikhak, M. Lim, B. Biedrzycki, F. Borellini, S. M. Clift, K. M. Hege, D. G. Ando, S. Piantadosi, et al.
Phase I/II Trial of an Allogeneic Cellular Immunotherapy in Hormone-Naive Prostate Cancer.
Clin. Cancer Res., June 1, 2006; 12(11): 3394 - 3401.
[Abstract] [Full Text] [PDF]


Home page
GlycobiologyHome page
T. Freire, R. Lo-Man, F. Piller, V. Piller, C. Leclerc, and S. Bay
Enzymatic large-scale synthesis of MUC6-Tn glycoconjugates for antitumor vaccination
Glycobiology, May 1, 2006; 16(5): 390 - 401.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
G. Ragupathi, N. X. Liu, C. Musselli, S. Powell, K. Lloyd, and P. O. Livingston
Antibodies against Tumor Cell Glycolipids and Proteins, but Not Mucins, Mediate Complement-Dependent Cytotoxicity
J. Immunol., May 1, 2005; 174(9): 5706 - 5712.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
S. J. Keding and S. J. Danishefsky
Natural Product Synthesis Special Feature: Prospects for total synthesis: A vision for a totally synthetic vaccine targeting epithelial tumors
PNAS, August 17, 2004; 101(33): 11937 - 11942.
[Abstract] [Full Text] [PDF]



About
JCO
 Editorial
Roster
 Advertising
Information
 Librarians &
Institutions
 Rights &
Permissions
 PDA Services

Copyright © 2003 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online